Science1 distinct publisher3 min readPublished
The oral bait work aimed at devil facial tumour disease has largely solved the hard part of dosing wild scavengers, so the constraint on protecting Australian mammals from H5N1 now sits in the vaccine pipeline.
The Scientist · Science desk
Compiled by The ScientistSomething wrong?How this is made
The reason a bait cannot simply carry the approved product is mechanical. Weakened or modified live viruses get into host cells readily enough to provoke an immune response, and a killed-virus formulation designed for a syringe does not, which the team gives as the reason it performs poorly in baits [9]. The nearest candidate on the right platform is American: a bird flu target inserted into a weakened human virus, which protected mice from bird flu and raised a similar immune response in cattle [10]. The authors note that design resembles both their devil tumour construct and the US rabies bait vaccine [19]. What that pair of results does not establish is protection in cattle. A comparable immune response is a measure of immunogenicity, not of survival, and neither a mouse nor a cow is a marsupial.
Scale is the other thing the rabies comparison brings with it. A billion baits since 1978 across 30 nations [1] averages roughly 21 million baits a year [1], near 700,000 per participating country per year [2], and that is the volume behind the rabies-free declarations [1]. The Tasmanian dispenser is a precision instrument by comparison, reading a microchip and a body temperature for each animal it serves and streaming the record home [4]. That is the right tool for a trial, and for settling a question the team is candid about not yet being able to answer, whether influenza would give a devil a fever [5]. Bulk coverage is a separate engineering problem, and the account does not report what fraction of a wild population the baits reach, only that several bait types were tested to raise uptake and that possums, quolls, pademelons and rats eat them as well [3].
The authors' case that a vaccine could arrive in useful time leans on COVID, where human testing began about two months after the novel coronavirus was sequenced [18]. Testing is not approval, and their own verdict on getting a wildlife bird flu vaccine approved within this outbreak is that it would be very challenging, though not impossible [7]. Meanwhile the delivery side is close to ready: with a suitable vaccine, they expect devils and other scavenging mammals could be covered quickly, and possibly land-scavenging bird colonies such as brown skuas, the first species found with bird flu in Australia [17].
Heard Island argues against assuming that vulnerability follows exposure. Six other bird and mammal species there were found infected, yet the mass die-off was confined to elephant seals, and one Australian fur seal has since died after infection [15]. That is the pattern behind the authors' admission that they cannot rank Australian species by risk in advance [12], and it favours spending on platforms that can be aimed at whichever species turns out to need them.
Ranked by verification strength, evidence, and original report placement.
In the United States, researchers trialled a vaccine that inserts a bird flu target into a weakened human virus; it protected mice from bird flu and induced a similar immune response in cattle.
The authors say the US vectored vaccine approach is similar to both their Tasmanian devil tumour vaccine and a highly successful US rabies bait vaccine.
Since 1978, 30 European nations have distributed a billion baits containing rabies vaccine, and many European nations are now considered rabies-free.
The research team began work in 2019 on an oral bait vaccine to help prevent transmission of devil facial tumour disease, a contagious cancer spread when devils tussle and bite.
In fieldwork the team tested a bait dispenser and several types of baits to increase how many are eaten by wild devils; possums, quolls, pademelons and rats also eat these baits.
The team developed a motion-activated smart bait dispenser that recognises devils in milliseconds and delivers bait, with a microchip scanner recording which animal likely took the bait and its current body temperature, transmitted in real time.
Distinct publishers with included, body-backed reporting in this cluster.
phys.org
1 article · August 27, 2026
Follow any of these and your For You feed starts watching them — no settings page required.
science
Whale-watch footage catches 1,417 humpbacks feeding along a corridor theory calls a fast1 distinct publisher
science
The 35C problem is a rostering problem: card data says afternoon trade does not come back until dark1 distinct publisher
science
A handful of Texan pumas saved the Florida panther. Genetics is still off the plan.1 distinct publisher
science
Most kingfish carrying the mushy-flesh parasite cook up firm, so the cook test misses them1 distinct publisher
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Specific but single-source and largely self-reported
The account carries concrete, checkable anchors - a billion baits across 30 nations since 1978, more than 13,000 elephant seal pup deaths on Heard Island with virus confirmed in carcasses, one Australian emergency-approved injectable vaccine, an up-to-10% official risk estimate - which lifts it above vague advocacy. But every load-bearing technical claim (millisecond devil recognition, bait-stable tumour-infecting construct, field bait uptake) is the authors' own unreferenced report in a single publisher's republication, with no peer-reviewed citation, no dispenser performance data and no identifier for the US vectored trial.
Delivery modality proven elsewhere; bird flu use not yet started
The bait modality itself has genuine large-scale adoption in the rabies programme, and the devil dispenser is in real fieldwork, which is more than a concept. But for the actual subject of the story - protecting Australian mammals from H5N1 - adoption is near zero: no bait-compatible bird flu vaccine exists, Australia's single emergency approval is an injectable for penguins and captive birds, in-devil trials of even the tumour vaccine have not begun, and pinnipeds are excluded from the approach entirely.
Delivery problem framed as more solved than the text supports
The cluster framing - that the hard part of dosing wild scavengers is largely solved and the bottleneck has moved to the vaccine bench - runs ahead of the source's own admissions. Bait uptake per animal remains unknown, non-target species eat the baits, the fever signal the telemetry is meant to read is unconfirmed, no in-devil trial has started, and the mass-mortality species are outside the method. The underlying facts are real and the authors are candid about gaps, so this is overstatement of readiness rather than fabrication.
Authors advocating for their own programme and for looser rules
The piece is written by the research team whose dispenser and vaccine it describes, and it closes with explicit asks: invest in new wildlife bird flu vaccines, speed up development, and relax strict dosing requirements and approval timelines. Those are direct funding and regulatory interests. It is transparently authored opinion-analysis republished under Creative Commons with no independent editing, though the authors do disclose several limitations against their own case.
Low-moderate: one publisher, one authored source
Assessment rests on a single article from a single publisher, written by interested parties, with no corroborating coverage, no primary documents and no named regulator or trial references. Internal consistency and specific figures support moderate confidence in what the authors claim to have built; confidence in readiness, scale and timelines is low.